Drug exec takes the Fifth on Capitol Hill, angers lawmakers

WASHINGTON (AP) — Infuriating members of Congress, a smirking Martin Shkreli took the Fifth at a Capitol Hill hearing Thursday when asked about his jacking up of drug prices, then promptly went on Twitter and insulted his questioners as "imbeciles." The brash, 32-year-old entrepreneur who has...

Mnet 60016 Drug Price Hikes Shkreli Ap Tn
 
              Pharmaceutical chief Martin Shkreli smiles on Capitol Hill in Washington, Thursday, Feb. 4, 2016, during the House Committee on Oversight and Reform Committee hearing on his former company's decision to raise the price of a lifesaving medicine. Shkreli refused to testify before U.S. lawmakers who excoriated him over severe hikes for a drug sold by a company that he acquired. (AP Photo/Susan Walsh)

WASHINGTON (AP) — Infuriating members of Congress, a smirking Martin Shkreli took the Fifth at a Capitol Hill hearing Thursday when asked about his jacking up of drug prices, then promptly went on Twitter and insulted his questioners as "imbeciles."

The brash, 32-year-old entrepreneur who has been vilified as the new face of pharmaceutical industry greed was summoned by the House Oversight and Government Reform Committee, which is investigating soaring prices for critical medicines.

Four times, he intoned: "On the advice of counsel, I invoke my Fifth Amendment privilege against self-incrimination and respectfully decline to answer your question."

At another point, he said: "I intend to follow the advice of my counsel and not yours."

Lawmakers erupted. Rep. Elijah Cummings of Maryland, the top Democrat on the committee, told Shkreli to wipe the smirk off his face.

"I call this money blood money ... coming out of the pockets of hardworking Americans," he said, as Shkreli sat through the lecture.

"I know you are smiling, but I am very serious, sir," Cummings said. "I truly believe you can become a force of tremendous good. All I ask is that you reflect on it. No, I don't ask, I beg that you reflect on it. "

The former hedge fund manager with a frat-boy swagger has been reviled in recent months for buying Daraprim, the only approved drug for a rare and sometimes deadly parasitic infection, and then unapologetically raising its price more than fiftyfold.

Shkreli is out on $5 million bail after being arrested in New York in December on securities-fraud charges unrelated to the price increase.

He was dismissed less than an hour into the hearing, but not before Chairman Rep. Jason Chaffetz, R-Utah, shouted down a request by Shkreli's attorney to speak. Lawmakers instead took turns denouncing his conduct and attitude.

Minutes after he left — and even before the hearing had ended — Shkreli thumbed his nose at the committee.

"Hard to accept that these imbeciles represent the people in our government," the former CEO of Turing Pharmaceuticals tweeted.

Shkreli's attorney Benjamin Brafman later said in his defense: "He meant no disrespect, but in truth, statements made by some of the members of the committee were wrong, unfair and difficult to listen to without responding."

Also appearing before the lawmakers were Turing's chief commercial officer and the interim CEO of Canada's largest drugmaker, Valeant Pharmaceuticals.

Documents from Valeant and Turing show they have made a practice of buying and then dramatically raising prices for low-cost drugs given to patients with life-threatening conditions such as heart disease, AIDS and cancer.

The two companies' executives insisted they are committed to ensuring that cost isn't a deterrent for patients who need the drugs.

With Shkreli mum, it was up to Turing's Nancy Retzlaff to defend the Daraprim price rise. She said about 3,000 people are treated with Daraprim, and only 25 percent are covered by commercial insurance. She added that the overall impact of the drug on the budget of commercial health plans "is very, very small."

Documents show how executives at both companies planned to maximize profits while fending off negative publicity.

As early as last May, Turing planned to turn Daraprim into a $200-million-a-year drug by dramatically increasing its price, according to documents obtained by the committee. Turing bought the 60-year-old drug in August for $55 million.

Shkreli said in an email to one contact: "We raised the price from $1,700 per bottle to $75,000. Should be a very handsome investment for all of us."

But the company also warned in an internal memo of a possible backlash from advocates for HIV patients.

As for Valeant, documents indicate the company believed it could repeatedly raise the prices of Nitropress and Isuprel without repercussions because the drugs are administered by hospitals, which are less price-sensitive than consumers.

___

AP Business Writer Tom Murphy in Indianapolis contributed to this report.

More in Home